Trial Enrollment and Survival Disparities Among Patients With Advanced Epithelial Ovarian Carcinoma
JAMA Network Open · 22.10.2025 · 8 (10) · e2538648
DOI: 10.1001/jamanetworkopen.2025.38648 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 22.10.2025. Verfasst von Caitlin Ruth Johnson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sutter Health, Walnut Creek, California. Hauptthemen laut MEDLINE: Carcinoma, Ovarian Epithelial, Healthcare Disparities, Ovarian Neoplasms, Patient Selection. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Racial differences in epithelial ovarian cancer (EOC) might result in survival inequities.
Objective
To evaluate enrollment and outcomes by race in Gynecologic Oncology Group (GOG) randomized clinical trials (RCTs) among patients with EOC. Design, Setting, and Participants This cohort study used ancillary data from completed RCTs using protocols GOG-111, GOG-114, GOG-158, and GOG-172 under a data sharing agreement with National Research Group Oncology. Patients with stage III or IV EOC in first-line RCT protocol GOG-111 had suboptimally resected disease, whereas those in GOG-114, GOG-158, or GOG-172 had optimally resected disease. RCTs were conducted and published between 1996 and 2006, and data for this study were analyzed in August 2024. Exposure Race was categorized as Asian, Black or African American (Black), or White or Caucasian (White). Patients of other races were excluded. Spanish ethnicity and additional details regarding residual disease status were not available for analysis. Main Outcomes and Measures Overall survival (OS) was the primary end point and progression-free survival (PFS) was the secondary end point, evaluated using multivariable Cox proportional-hazards modeling and log-rank testing. Statistical significance was set at P < .05.
Results
This study included 1903 evaluable participants, of whom 35 (1.84%) self-identified as Asian, 121 (6.36%) as Black, and 1747 (91.80%) as White. Black patients had lower OS (median [IQR], 36.8 [19.2-73.4] months) than Asian (50.9 [23.9-109.2] months) or White (48.4 [24.5-93.4] months) patients ( P = .03), with a higher risk of death than White patients (adjusted hazard ratio, 1.30; 95% CI, 1.06-1.59; P = .01). PFS and adjusted risk of disease progression were statistically similar across racial groups. Median (IQR) PFS was 18.9 (9.7-84.6), 18.0 (9.1-34.0), and 19.7 (11.5-43.3) months among Asian, Black, and White patients, respectively ( P = .08). Adjusted risk of disease progression was similar for Black patients compared with White patients (adjusted hazard ratio, 1.21; 95% CI, 1.00-1.47; P = .06). Conclusions and Relevance In this cohort study, Black and Asian patients were underrepresented in RCT trial populations. Black patients had lower OS than White and Asian patients but similar PFS. Equitable enrollment in clinical trials ensures access to cutting-edge treatments and can lead to outcomes comparable to those of White counterparts. Sustained efforts to improve RCT diversity remain essential to long-term equity in cancer care and survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Sutter Health, Walnut Creek, California.
- Department of Obstetrics and Gynecology, University of California, Irvine, Orange.
- Department of Obstetrics and Gynecology, University of California, Los Angeles.
- Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California.
- Gynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, Maryland.
- The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., Bethesda, Maryland.
Zitieren
APA
Johnson, C. R., Francoeur, A. A., Grewal, A., Ayoub, N. L., Richardson, M. T., Kapp, D. S., Darcy, K. M., Tian, C., & Chan, J. K. (2025). Trial Enrollment and Survival Disparities Among Patients With Advanced Epithelial Ovarian Carcinoma. JAMA Network Open, 8(10), e2538648. https://doi.org/10.1001/jamanetworkopen.2025.38648
Vancouver
Johnson CR, Francoeur AA, Grewal A, Ayoub NL, Richardson MT, Kapp DS, et al. Trial Enrollment and Survival Disparities Among Patients With Advanced Epithelial Ovarian Carcinoma. JAMA Network Open. 2025;8(10):e2538648. doi:10.1001/jamanetworkopen.2025.38648
BibTeX
@article{Johnson2025,
author = {Johnson, Caitlin Ruth and Francoeur, Alex A and Grewal, Amandeep and Ayoub, Natalie L and Richardson, Michael T and Kapp, Daniel S and Darcy, Kathleen M and Tian, Chunqiao and Chan, John K},
title = {Trial Enrollment and Survival Disparities Among Patients With Advanced Epithelial Ovarian Carcinoma},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {10},
pages = {e2538648},
doi = {10.1001/jamanetworkopen.2025.38648}
}
EUVIMED